[company_age]2.0[/company_age][employees]11-50 employees[/employees][description]Theriva Biologics is a clinical-stage immuno-oncology company focused on developing oncolytic viruses for the treatment of solid tumors. Their oncolytic viruses are engineered for systemic delivery and selective tumor destruction, overcoming the limitations of traditional oncolytic viruses. Theriva's unique approach involves degrading the tumor's protective barrier, enabling the virus to reach and destroy cancer cells while minimizing damage to healthy tissues. This strategy also enhances the efficacy of other cancer therapies, such as chemotherapy and immunotherapy. Theriva's lead candidate, VCN-01, is currently in a Phase 2 clinical trial for pancreatic ductal adenocarcinoma and is being investigated in other indications. The company is also developing the Albumin Shield™ technology to protect oncolytic viruses from circulating antibodies, allowing for multiple dosing cycles. Theriva's innovative approach and promising clinical data position them as a leader in the field of oncolytic virus therapy.[/description][ps]Oncolytic viruses for cancer treatment[/ps]